| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.9 |
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | -0.0019 | 1 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.0029 | 1 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.003 | 1 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | -0.0021 | 1 |